All News
Filter News
Found 806,088 articles
-
Cirius Therapeutics Announces Presentation of Interim Data from Phase 2b Clinical Study of MSDC-0602K at The International Liver Congress 2019
4/12/2019
Cirius Therapeutics announced today that positive results from an interim analysis of exploratory endpoints from the EMMINENCE trial, its ongoing Phase 2b clinical trial evaluating MSDC-0602K in 402 patients diagnosed with non-alcoholic steatohepatitis (NASH) with fibrosis, were presented at The International Liver Congress™ 2019, occurring in Vienna, Austria, from April 10 to 14, 2019.
-
Vaxart to Present at the 29th European Congress of Clinical Microbiology & Infectious Diseases
4/12/2019
100% Survival Against Lethal H5N1 Avian Flu Challenge in Ferret Study
-
Bristol-Myers Squibb Shareholders Approve Celgene Acquisition
4/12/2019
Bristol-Myers Squibb Company (NYSE: BMY) today announced that its shareholders voted to approve the issuance of shares of Bristol-Myers Squibb common stock in connection with the Company’s pending merger with Celgene Corporation (NASDAQ:CELG) at the Special Meeting of Stockholders.
-
Fidia Pharma USA Inc. Announces Expansion into the Dietary Supplement Market with Launch of CartiJoint™ FORTE
4/12/2019
CartiJoint™ FORTE is the First Product in Fidia’s New Dietary Supplement Portfolio; Uniquely formulated with bioactive Bio-Curcumin Curcugreen™*
-
CHG Healthcare Names Kevin Ricklefs Chief Culture Officer
4/12/2019
CHG Healthcare, the nation's largest privately held healthcare staffing company, has named Kevin Ricklefs chief culture officer.
-
Vertex to Announce First-Quarter 2019 Financial Results on April 30
4/12/2019
Vertex Pharmaceuticals Incorporated will report its first quarter 2019 financial results on Tuesday, April 30, 2019 after the financial markets close.
-
Celling Biosciences, a pioneer in cellular therapy, acquires rights to ThermiGen
4/12/2019
Celling Biosciences ("Celling"), based in Austin, Texas, acquired all the assets and stock of ThermiGen, the aesthetic device division of Spanish pharmaceutical leader Almirall.
-
Horizon Pharma plc to Present Results from its Phase 3 Teprotumumab Trial (OPTIC) at the 2019 American Association of Clinical Endocrinologists (AACE) Scientific and Clinical Congress
4/12/2019
Horizon Pharma plc announced that it will present additional results from its Phase 3 confirmatory clinical trial evaluating teprotumumab for the treatment of active thyroid eye disease at the 2019 American Association of Clinical Endocrinologists 28th Annual Scientific & Clinical Congress.
-
CONMED Corporation Announces Amended Start Time for Annual Meeting of Shareholders
4/12/2019
CONMED Corporation (NASDAQ: CNMD) today announced an amended start time for its Annual Meeting of Shareholders
-
World Bank DC Meeting: AHF to Spark Conversations over Free Coffee Friday, 4/12
4/12/2019
Advocates with the largest global AIDS organization trade coffee for conversation in an effort to “Raise the MIC” and spotlight the World Bank’s harmful country classification system.
-
X4 Pharmaceuticals Prices $85.8 Million Public Offering of Common Stock and Class A Warrants
4/12/2019
X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for the treatment of rare diseases, announced today the pricing of its previously announced underwritten public offering of 5,670,000 shares of its common stock
-
Atlas Venture, F-Prime Capital, RA Capital Management, and Osage University Partners to Host Second Annual Science2Startup Symposium
4/12/2019
Science2Startup Symposium Will Take Place in Cambridge on April 23, 2019, at the Broad Institute of MIT and Harvard
-
Rising Shanghai Biotech Firms Shine at AACR Annual Meeting 2019
4/12/2019
Genbase Biotechnology unveils innovative new drug research for treatment of gastric/pancreatic cancer and solid tumors
-
Canopy Growth to join the S&P/TSX 60 Index
4/12/2019
Canopy Growth Corporation (TSX: WEED) (NYSE: CGC) ("Canopy Growth" or "the Company") today announced that the Company is to join the S&P/TSX 60 Index, achieving another public market "first" for the cannabis industry.
-
Gofire Taps Industry Veteran Joe Hodas to Help Lead Plant-based Medicine Healthcare Revolution
4/12/2019
As President, Hodas will help drive day-to-day operations, including marketing and sales, as the company prepares to launch its patent-pending Gofire Inhaler
-
GlycoMimetics Announces Plans to Initiate Breast Cancer Trial to Evaluate GMI-1359
4/12/2019
GlycoMimetics, Inc. (NASDAQ: GLYC) today announced plans to initiate a clinical trial of GMI-1359 in breast cancer patients whose tumors have spread to bone
-
Tikcro Technologies Reports Fourth Quarter and Full Year 2018 Results
4/12/2019
High Level Pre-Clinical Results Showed in AACR 2019 Annual Conference
-
Dr. Jonathan Greenburg, Foremost Expert on Snoring and Sleep Apnea, Provides HappyZ Tips for Better Sleep Month
4/12/2019
Dr. Jonathan Greenburg, DDS, preeminent U.S. expert on snoring and sleep apnea who #SnoreSolved Shaquille O'Neal's sleep issues, is offering tips on how to get "happy Z's" in time for Better Sleep Month in May.
-
Alexion to Report First Quarter Results on Thursday, April 25, 2019
4/12/2019
Alexion Pharmaceuticals, Inc. announced that the Company will report its financial results for the first quarter ended March 31, 2019 before the US financial markets open on April 25, 2019.
-
Ajax Health Raises More Than $85 Million to Advance Medical Device Innovations
4/12/2019
Ajax Health II, the latest medical device venture from serial healthcare entrepreneur Duke Rohlen, announced today that it has raised more than $85 million, which will be used to strategically operate and expand innovative medical device companies